Investment bank Morgan Stanley has highlighted three major biotechnology breakthroughs—Alzheimer's treatments, in-vivo gene editing, and artificial intelligence—as key multi-billion dollar investment opportunities during its Global Healthcare Conference in New York.
Key Takeaways
- Morgan Stanley sizes the total Alzheimer's drug market at $70 billion, split between slowing cognitive decline and treating behavioral symptoms.
- Analysts forecast the in-vivo gene editing market will hit $10 billion by 2035, outpacing the industry consensus of $6 billion.
- Using AI in drug discovery could reduce timelines from 4.5 years to 1.5 years and cut R&D costs by 25% to 60%.
- Chief strategist Mike Wilson warned in mid-September of a market correction within 30 days if rising oil prices drain liquidity.
Alzheimer's Care and In-Vivo Gene Editing Opportunities
In a research report authored by analysts Sean Laaman and Maxwell Skor, Morgan Stanley details how delaying nursing home entry for patients by 12 to 18 months could generate healthcare value worth multiples of drug list prices. Beyond pharmaceutical developers, diagnostic companies, care delivery providers, retirement facilities, and insurers stand to benefit.
Simultaneously, the bank points to a structural shift in genetic medicine. While early gene therapies operated ex vivo by editing cells outside the body, newer in-vivo platforms edit DNA directly inside organs such as the brain, heart, eyes, and liver. With sector performance climbing since mid-2025, critical clinical data expected over the next 18 months will determine how markets value these next-generation platforms.
AI Infrastructure and Macro Vulnerabilities
While AI can significantly shorten drug discovery periods, analysts noted there is little evidence yet that algorithm-driven design increases the likelihood of final regulatory approval. Consequently, Morgan Stanley favors "picks and shovels" suppliers—businesses providing data, laboratory tools, and computing power—over clinical drug developers. This preference reflects broader market trends where compute providers profit from tech expansion, similar to growing AI data center infrastructure demand.
However, clinical trial outcomes continue to drive extreme volatility, as seen during Moderna's share rally in August following late-stage cancer vaccine data. Macro risks also remain a factor for valuation metrics, particularly as broader commodity movements and crude oil market shifts threaten equity liquidity.
Why It Matters
This research highlights an institutional shift toward backend infrastructure in specialized sectors. By favoring tool providers over binary clinical trial bets, institutional investors are looking to minimize downside risks while maintaining exposure to AI productivity gains. Furthermore, if in-vivo therapies meet Morgan Stanley's $10 billion projection over consensus, genetic medicine could see a rapid reallocation of capital over the coming 18 months.
